Abstract

Mifepristone, a synthetic steroid with potent antiprogestational and antiglucocorticoid activity, has established itself as a versatile pharmacological agent with significant clinical implications. Initially approved for medical termination of early pregnancy, mifepristone functions by competitively inhibiting progesterone receptors, disrupting endometrial support and promoting uterine contractility when used alongside prostaglandins. Its clinical utility, however, extends well beyond reproductive health. It is employed in cervical ripening, second-trimester abortion, and labor induction. Furthermore, mifepristone has demonstrated therapeutic potential in the management of uterine fibroids, endometriosis, and as a targeted treatment in Cushing’s syndrome by modulating glucocorticoid receptors. Emerging research also explores its role in treating hormone-sensitive malignancies, including breast and ovarian cancers. As evidence continues to grow, mifepristone represents a promising tool in both gynecological and endocrine therapy, warranting further exploration and integration into broader clinical practice.

• 1.   Autry, B. M., & Wadhwa, R. (2024). Mifepristone. In StatPearls. StatPearls Publishing.
• 2.   Alka B. Patil, G. Garima, G. Garima. Clinical applications of mifepristone in obstetrics and gynaecology Clinical applications of mifepristone in obstetrics and gynaecology. International Journal of Recent Trends in Science and Technology nd Technology June 2014; 11(2): 180-186 http://www.statperson.com
• 3.   Tieszen, C.R., Goyeneche, A.A., Brandhagen, B.N. et al. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 11, 207 (2011). https://doi.org/10.1186/1471- 2407-11-207
• 4.   Annu. Rev. Med. 1997. 48:129–56 RU486 (Mifepristone): Mechanisms of Action and Clinical Uses F. Cadepond, PhD, A. Ulmann, 94276 1RousselUclaf, France.
• 5.   Yu, S., Yang, X., Zhu, Y. et al. Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAKSrc-Paxillin complex. Sci Rep 5, 7830 (2015). https://doi.org/10.1038/srep07830
• 6.   Safe abortion Clinical practice handbook of World Health Organization 2014.
• 7.   Clinical Medicine Insights: Reproductive Health 2013:7 23 Emerging Options for Emergency Contraception Atsuko Koyama1, Laura Hagopian2 and Judith Linden2.
• 8.   Royal College of Obstetricians and Gynaecologists. The care of women requesting induced abortion: evidence-based clinical guideline number 7
• 9.   Royal College of Obstetricians and Gynaecologists (RCOG) Late intrauterine fetal death and stillbirth Royal College of Obstetricians and Gynaecologists (RCOG), London (UK), 2010.
• 10.   Wagaarachchi, P.T. Ashok, P.W. Narvekar, N.N. Medical management of late intrauterine death using a combination of mifepristone and misoprostol.
• 11.   Effects of a preovulatory single low dose of mifepristone on ovarian function. van der Stege JG, Pahl-van Beest EH, Beerthuizen RJ, van Lunsen RH, Scholten PC, Bogchelman DH. Eur J Contracept Reprod Health Care. 2006;11:104–108. doi: 10.1080/13625180500539505.
• 12.   Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. Paulson RJ, Sauer MV, Lobo RA.
• 13.   Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC.
• 14.   Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486) Kettel LM, Murphy AA, Morales AJ, Yen SS. Am J Obstet Gynecol. 1998;178:1151–1156. doi: 10.1016/s0002-9378(98)70316-3.
• 15.   The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. Che X, Wang J, He J, Guo X, Li T, Zhang X. Int J Med Sci. 2020;17:224–233. doi: 10.7150/ijms.39252.
• 16.   Medical management of Cushing’s disease Alan Kelsall
• 17.   Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. Ji Y, Rankin C, Grunberg S, et al. J Clin Oncol. 2015;33:4093–4098. doi: 10.1200/JCO.2015.61.6490
• 18.   A Reference Guide to Fetal and Neonatal Risk Briggs Drugs in Pregnancy and Lactation Twelfth Edition.
• 19.   Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jul 18, 2022. Mifepristone.
• 20.   The WHO abortion care guideline: Law and policy Past, present, and future Joanna N. Erdman.

Data Sharing Statement

Funding